Terms: = Breast cancer AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2 AND Treatment
4 results:
1. The ranbp2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis.
Blondel-Tepaz E; Leverve M; Sokrat B; Paradis JS; Kosic M; Saha K; Auffray C; Lima-Fernandes E; Zamborlini A; Poupon A; Gaboury L; Findlay J; Baillie GS; Enslen H; Bouvier M; Angers S; Marullo S; Scott MGH
Oncogene; 2021 Mar; 40(12):2243-2257. PubMed ID: 33649538
[TBL] [Abstract] [Full Text] [Related]
2. Targeting zinc finger domains with small molecules: solution structure and binding studies of the ranbp2-type zinc finger of RBM5.
Farina B; Fattorusso R; Pellecchia M
Chembiochem; 2011 Dec; 12(18):2837-45. PubMed ID: 22162216
[TBL] [Abstract] [Full Text] [Related]
3. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.
Vincze B; Pályi I; Gaál D; Pató J; Móra M; Mezõ I; Teplán I; Seprõdi J
Cancer Detect Prev; 1996; 20(2):153-9. PubMed ID: 8706041
[TBL] [Abstract] [Full Text] [Related]
4. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract] [Full Text] [Related]
